Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00836069 · ClinicalTrials.gov registry record · Phase 3
Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder
A Phase 3 study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT00836069: Clinical Trial Phase 3 study, sponsored by Cedars-Sinai Medical Center.
NCT00836069 is a Phase 3 study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 5 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00836069, a Phase 3 study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, parallel-group, multi-site, Phase 3, placebo controlled fixed-dose study of PD 0332334 and paroxetine in 528 outpatients with generalized anxiety disorder. Subjects will be randomized to the following treatments (132 subjects per treatment group): PD 0332334 225 mg twice a day (450 mg/day), PD 0332334 300 mg twice a day (600 mg/day), placebo once a day in the morning or paroxetine 20 mg once a day in the morning (20 mg/day).
Primary Outcome
The purpose of administering the scale is to analyze the severity of the patient's anxiety and will take approximately 10 to 15 minutes to administer.
Interventions
- DRUG Placebo
- DRUG Paroxetine
- DRUG No drug name provided by Sponsor; drug referenced as PD 0332334
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Why NCT00836069 stopped before completion
NCT00836069 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00836069 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00836069 about?
NCT00836069 is a clinical study titled "Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder". This study is a randomized, double-blind, parallel-group, multi-site, Phase 3, placebo controlled fixed-dose study of PD 0332334 and paroxetine in 528 outpatients with generalized anxiety disorder. Subjects will be randomized to the following treatments (132 subjects per treatment group): PD 033233...
What is the current status of trial NCT00836069?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2008-10. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00836069?
The interventions under investigation include: Placebo (DRUG), Paroxetine (DRUG), No drug name provided by Sponsor; drug referenced as PD 0332334 (DRUG).
Who is sponsoring clinical trial NCT00836069?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00836069's enrollment target sits among peer trials
5 1997th of 2000 higher than 3 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia